Financials data is unavailable for this security.
View more
Year on year Allergy Therapeutics PLC had revenues fall -7.36% from 59.59m to 55.20m, though the company grew net income from a loss of 43.07m to a smaller loss of 40.22m.
| Gross margin | 53.87% |
|---|---|
| Net profit margin | -72.86% |
| Operating margin | -63.87% |
| Return on assets | -61.12% |
|---|---|
| Return on equity | -1,392.76% |
| Return on investment | -86.97% |
More ▼
Cash flow in GBPView more
In 2024, cash reserves at Allergy Therapeutics PLC fell by 1.93m. Cash Flow from Financing totalled 31.43m or 56.94% of revenues. In addition the company used 32.14m for operations while cash used for investing totalled 1.20m.
| Cash flow per share | -0.0089 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0008 |
|---|---|
| Tangible book value per share | -0.0002 |
More ▼
Balance sheet in GBPView more
| Current ratio | 1.63 |
|---|---|
| Quick ratio | 1.01 |
| Total debt/total equity | 8.35 |
|---|---|
| Total debt/total capital | 0.8931 |
More ▼
Growth rates in GBP
Year on year, growth in earnings per share excluding extraordinary items increased 63.69%.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 63.47 |
